Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

BACKGROUND: Although several COVID-19 vaccines have been developed so far, they will not be sufficient to meet the global demand. Development of a wider range of vaccines, with different mechanisms of action, could help control the spread of SARS-CoV-2 globally. We developed a protein subunit vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shilong, Li, Yan, Dai, Lianpan, Wang, Jianfeng, He, Peng, Li, Changgui, Fang, Xin, Wang, Chenfei, Zhao, Xiang, Huang, Enqi, Wu, Changwei, Zhong, Zaixin, Wang, Fengze, Duan, Xiaomin, Tian, Siyu, Wu, Lili, Liu, Yan, Luo, Yi, Chen, Zhihai, Li, Fangjun, Li, Junhua, Yu, Xian, Ren, Hong, Liu, Lihong, Meng, Shufang, Yan, Jinghua, Hu, Zhongyu, Gao, Lidong, Gao, George F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990482/
https://www.ncbi.nlm.nih.gov/pubmed/33773111
http://dx.doi.org/10.1016/S1473-3099(21)00127-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990482/
https://www.ncbi.nlm.nih.gov/pubmed/33773111
http://dx.doi.org/10.1016/S1473-3099(21)00127-4

Ejemplares similares